Reported 7 months ago
Insmed Incorporated's stock has surged by up to 110% after announcing positive results from a study on treating the lung condition bronchiectasis. The pharmaceutical company plans to file for US market clearance later in the year and launch in 2025, with potential applications for other diseases. Analysts are optimistic about these developments, seeing them as transformative for the company and a key driver of value, providing relief to investors and opening up financing possibilities.
Source: YAHOO